Diffuse large B-cell lymphoma on the back of a patient with AIDS: Successful treatment by the CD20 monoclonal antibody rituximab [5]

International Journal of Dermatology

Volumn 44, Issue 11, 2005, Pages 976-978

  Voigtländer, Constanze ^a,b   Harrer, Thomas ^a,b   Schneider, Lothar ^a,b   Schulze Koops, Hendrik ^a,b   Niedobitek, Gerald ^a,b   Lüftl, Matthias ^a,b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTICONVULSIVE AGENT; ANTIVIRUS AGENT; CD20 ANTIBODY; CD20 ANTIGEN; COTRIMOXAZOLE; FOLINATE CALCIUM; GABAPENTIN; LAMIVUDINE; LOPINAVIR; PREDNISOLONE; PYRIMETHAMINE; RITONAVIR; RITUXIMAB; SULFUR DERIVATIVE; TENOFOVIR; VALPROIC ACID; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; B CELL LYMPHOMA; BRONCHOSPASM; CASE REPORT; CHILL; CLINICAL FEATURE; DRUG COST; DRUG DOSE REGIMEN; DYSPNEA; ENCEPHALITIS; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPOTENSION; HYPOXIA; LETTER; MALE; QUALITY OF LIFE; RIGOR; SKIN BIOPSY; SKIN LYMPHOMA; SKIN NODULE; TOXOPLASMOSIS; URTICARIA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THORAX; TREATMENT OUTCOME;

EID: 28444458913     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2005.02649.x     Document Type: Letter

References (10)

1. Russell-Jones R. World Health Organization classification of haematopoietic and lymphoid tissues: Implications for dermatology. J Am Acad Dermatol 2003; 48: 93-102.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
3. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998; 10: 548-551.
4. Spina M, Sparano JA, Jaeger U, et al. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. AIDS 2003; 17: 137-138.
5. Foran JM, Gupta RK, Cunningham D, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000; 109: 81-88.
6. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
7. Kerschmann RL, Berger TG, Weiss LM, et al. Cutaneous presentations of lymphoma in human immunodeficiency virus disease. Predominance of T cell lineage. Arch Dermatol 1995; 131: 1281-1288.
8. Beylot-Barry M, Vergier B, Masquelier B, et al. The Spectrum of Cutaneous Lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol 1999; 23: 1208-1216.
9. Berti E, Alessi E, Caputo R, et al. Reticulohistiocytoma of the dorsum. J Am Acad Dermatol 1988; 19: 259-272.
10. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-371.